A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Inclusion Criteria: * Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments * Histologic confirmation of the original primary tumor is required * Histologic or cytologic confirmation of the recurrent/progressive disease is desired * Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma * Disease that is measurable per RECIST v1.1 * No active infection requiring antibiotics * Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment * Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment * Adequate hematologic and end organ function Exclusion Criteria: * Type I diabetes or Type II diabetes requiring insulin * Prior use of mTOR/PI3K inhibitor * Current dyspnea at rest or any requirement for supplemental oxygen therapy to perform activities of daily living * Previous diagnosis of pulmonary fibrosis of any cause * History of myocardial infarction or unstable angina within 6 months prior to first study treatment * Congestive heart failure * History of malabsorption syndrome or other condition that would interfere with enteral absorption * Clinically significant history of liver disease, including cirrhosis and current alcohol abuse * Presence of positive test results for hepatitis B or hepatitis C * Known HIV infection * Active autoimmune disease that is not controlled by nonsteroidal anti inflammatory drugs * Need for current chronic corticosteroid therapy * Pregnancy, lactation, or breastfeeding * Current severe, uncontrolled systemic disease * Major surgical procedure or significant traumatic injury within 28 days prior to Day 1 or anticipation of the need for major surgery during the course of study treatment * Uncontrolled hypercalcemia * Leptomeningeal disease as a manifestation of cancer * Known untreated or active brain metastases * Grade \>=2 hypercholesterolemia or hypertriglyceridemia